Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631927 | 0.90 | HPGD (0.52) | KMT2AMEN1HPGDALDH1A1TSHR | |
| SCHEMBL6498810 | 0.87 | CHRNB2 (0.46) | KMT2AMEN1HPGDALDH1A1TSHR | |
| SCHEMBL6486768 | 0.84 | HPGD (0.50) | HPGDALDH1A1TSHRCHRNB2CHRNB4 | |
| SCHEMBL6488167 | 0.80 | S1PR4 (0.43) | KMT2AMEN1HPGDALDH1A1CHRNB2 | |
| SCHEMBL6500809 | 0.79 | NPC1 (0.43) | KMT2AMEN1HPGDALDH1A1NPC1 | |
| SCHEMBL6497293 | 0.78 | NPC1 (0.56) | HPGDALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL6500583 | 0.78 | NPC1 (0.42) | KMT2AMEN1HPGDALDH1A1NPC1 | |
| SCHEMBL6501627 | 0.78 | MMP13 (0.43) | KMT2AMEN1HPGDALDH1A1NPC1 | |
| SCHEMBL6489260 | 0.78 | ALDH1A1 (0.49) | KMT2AMEN1HPGDALDH1A1NPC1 | |
| SCHEMBL6486252 | 0.77 | RAB9A (0.41) | KMT2AMEN1HPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | KMT2A 3836/4885MEN1 1004/4885HPGD 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.